CureVac begins Phase II trial of Covid-19 vaccine
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
CureVac has started dosing participants in a Phase IIa clinical trial of its messenger RNA (mRNA)-based Covid-19 vaccine candidate, CVnCoV.

The dose-confirmation study, CV-NCOV-002, is being carried out in Peru and Panama. It will enrol 690 healthy participants across adults aged 61 or above and those aged 18-60.

Each participant will be administered with two CVnCoV vaccines, 28 days apart. Study will test different dose levels, starting from 6µg. The goal is to analyse the safety and reactogenicity of the vaccine in older adults.

Furthermore, the humoral immune response with CVnCoV will be evaluated and the safety database will be expanded to progress into a Phase IIb/III trial.

Preliminary Phase IIa results in older adults are expected to be reported in the fourth quarter of the year.

Source: https://www.clinicaltrialsarena.com/news/curevac-phase-iia-trial-covid-19/
Like
Comment
Share